Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRTX
DateTimeSourceHeadlineSymbolCompany
09/04/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
09/04/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/30/20244:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/30/20244:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/22/20248:00AMBusiness WireVertex to Participate in Upcoming September Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/16/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
08/12/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/08/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/08/202411:47AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/07/20247:12PMBusiness WireVertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in EnglandNASDAQ:VRTXVertex Pharmaceuticals Inc
08/07/20249:52AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/02/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/02/20244:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
08/01/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/01/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
08/01/20244:01PMBusiness WireVertex Reports Second Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
08/01/20243:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/30/20243:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/30/20241:10PMBusiness WireVertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute PainNASDAQ:VRTXVertex Pharmaceuticals Inc
07/25/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/24/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/24/202412:27PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/22/20241:16PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/17/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/15/20249:00AMPR Newswire (Canada)Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations raresNASDAQ:VRTXVertex Pharmaceuticals Inc
07/15/20249:00AMPR Newswire (Canada)Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare MutationsNASDAQ:VRTXVertex Pharmaceuticals Inc
07/12/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/10/202410:27AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
07/02/20248:33AMBusiness WireVertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
07/01/20244:05PMBusiness WireVertex to Announce Second Quarter 2024 Financial Results on August 1NASDAQ:VRTXVertex Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRTX